Regeneron Pharmaceuticals and Sanofi’s anti-inflammatory drug Dupixent (dupilumab) has shown to be effective against five types of type 2 inflammations, with more indications expected to surface soon.
AstraZeneca Plc said the company’s asthma treatment Fasenra for a chronic inflammatory disease of the nasal passage linings, or sinuses, met main goals in a late-stage study.
Lyra Therapeutics Announces $29.5 Million Series B Financing to Advance Innovative Therapeutics for Ear, Nose and Throat Diseases
Biotech, Biotechnology, Business, Clinical Trials, Ear, ENT Diseases, Nose and Throat (ENT) Diseases, Rhinosinusitis, Series B, Sinonasal Tissue, U.S. Centers for Disease Control and PreventionLyra Therapeutics Inc., a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat (ENT) diseases, announced a $29.5 million Series B equity financing.